Report an error

Spotted something inaccurate in “Dual SGLT1/2 Inhibitor Sotagliflozin Cuts Atherosclerosis Via Hepatic Fat Reprogramming”? Tell us what’s wrong and we’ll check it against the original source.

Website

Send report Cancel

This form is for factual corrections. We read every report but cannot reply individually.